Bionomics (NASDAQ:BNOX – Get Rating)'s stock had its "in-line" rating reaffirmed by Evercore ISI in a note issued to investors on Tuesday, Benzinga reports. They currently have a $6.00 price target on the stock, down from their previous price target of $17.00. Evercore ISI's price target would suggest a potential upside of 20.24% from the stock's previous close.

Several other research analysts also recently commented on the stock. HC Wainwright downgraded shares of Bionomics from a "buy" rating to a "neutral" rating in a research note on Monday. Loop Capital began coverage on shares of Bionomics in a report on Tuesday, November 1st. They issued a "buy" rating and a $23.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Bionomics presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.67.

Bionomics Price Performance

BNOX stock traded down $0.90 during trading on Tuesday, hitting $4.99. 1 shares of the company's stock traded hands, compared to its average volume of 5,746. Bionomics has a 52 week low of $5.30 and a 52 week high of $13.76. The business has a fifty day simple moving average of $7.67 and a 200 day simple moving average of $7.39.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

See Also

• Get a free copy of the StockNews.com research report on Bionomics (BNOX)
• General Mills Retreats To More Attractive Territory
• Will Tesla Shares Rally If Musk Steps Down From Twitter?
• Can Chewy Fetch Double Digit Gains in 2023?
• 5 Down But Not Out Stocks To Watch For 2023
• Eli Lilly Expects Enduring Growth, Despite Immediate Challenges

Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.